Table 6.
Annual probability of improvement according to the chelation regime. Irrespective of the regime to which the event was attributed, patients subsequently may have changed regime explaining the increasing number of patients in the non-DFO regimes compared to the number of events that were attributed to those regimes
| DFO |
DFP |
Comb |
|
|---|---|---|---|
| Year | Improvements/exposed1 % (95% C.I.) | Improvements/exposed % (95% C.I.) | Improvements/exposed % (95% C.I.) |
| 2000 | 2/39 5.1 (0.6–17.3) | 0/1 0 (0–97.5)2 | 0/0 (n.a.) |
| 2001 | 1/42 2.4 (0.06–12.6) | 0/1 0 (0–97.5)2 | 0/1 0 (0–97.5)2 |
| 2002 | 0/32 0 (0–10.9)2 | 0/6 0 (0–45.9)2 | 0/14 0 (0–20.6)2 |
| 2003 | 0/21 0 (0–16.1)2 | 1/12 8.3 (0.2–38.5) | 2/24 8.3 (1–27) |
| 2004 | 0/19 0 (0–17.6)2 | 1/16 6.2 (0.2–30.2) | 0/24 0 (0–14.2)2 |
| 2005 | 0/11 0 (0–28.5)2 | 2/15 13.3 (1.6–40.4) | 0/34 0 (0–10.3)2 |
| 2006 | 0/7 0 (0–40.9)2 | 1/14 7.1 (0.2–33.9) | 3/38 7.9 (1.6–21.4) |
| 2007 | 0/5 0 (0–52.2)2 | 3/11 27.3 (6–61) | 7/36 19.4 (8.2–36.1) |
| 2008 | 0/4 0 (0–60.2)2 | 1/9 11.1 (0.3–48.2) | 5/29 17.2 (5.8–35.8) |
DFO, desferrioxamine; DFP, deferiprone.
1
Number of persons with heart disease in each treatment group.
2
One-sided, 97.5% confidence interval.